Background and aims In the primary prevention setting, low-dose aspirin reduces major vascular events (MVEs) by approximately ...

Since the advent of drug-eluting stents, there has been a debate in the intervention community over how long dual ...

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that management will present at the TD Cowen 45th Annual Health Care ...